
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), followed by paclitaxel, trastuzumab and pertuzumab (THP), has shown pathologic complete response (pCR) rate improvement in the randomised DESTINY-Breast11 Phase III trial. The study is …